Skip to main content
Connect with coperate & third party planners-Eventen

Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has successfully completed the first 100 clinical batches of liquid and lyophilized vials at its dedicated site in Rankweil, Austria. 

“Since opening our state-of-the-art clinical production site in Austria three years ago, we have witnessed a rapid rise in customer demand, to which we’ve responded by completing 100 clinical batches, with more on the horizon,” shared Dr. Claus Feussner, Senior Vice President of Vetter Development Service. “The facility is the European counterpart to our clinical manufacturing site near Chicago, Illinois, U.S., and we are proud to see both sites outperforming our expectations. It is a tribute, not only to the quality of the drug product candidates we manufacture with our customers, but the reliability we provide to them and their patients.”

In response to the current growth, Vetter is further investing in its Rankweil site. This includes a 14-by-24-meter roof extension, which will add a third floor to the building, creating more office space with individual workstations, cluster-style offices, and meeting rooms. An additional technical building will be built on the West side of the existing facility. This 3,400 square-meters, two-story building will house a technical workshop and a waste disposal center.

The basement of the building will feature an innovative uninterrupted power supply system which prevents harmful power disruptions for its operations. The new equipment makes the Rankweil site self-sufficient in power supply, which further increases production security. This supports Vetter’s commitment to best-in-class quality standards and improves the efficiency of the manufacturing processes. These construction plans are set to be finalized by mid-2025.

“It has been exciting few years for the Rankweil site,” said Dr. Martin Schwab, Vice President and Site Head Austria. “We look forward to witnessing this site continue to develop and grow. Our success is driven by a strong surge in project orders which will continue in the second half of the year. We are committed to further enhancing our clinical production efficiency in Rankweil, both through increased security initiatives, innovative technology, and a higher number of employees working at the site.”

To learn about the newest innovations for aseptic processing, attend talks from industry leaders and network with peers, reserve your seat for the Innovatrix ‘3rd Aseptic BioPharma Processing Summit’ in Vienna, Austria, on October 29–30, 2024.

For more information, visit our website or email us at info@innovatrix.eu for the event agenda.

Source:

BusinessWire

Share this post:

Most Popular

Explore our best-read blogs and find out why your
industry trusts Innovatrix

How Rising Temperatures Will Affect Your Gigafactory Efficiency

Increasing humidity levels pose a challenge to dehumidification systems maintaining...

Continue reading
August 6, 2024 3 Mins Read
What do the new Annex 1 guidelines mean for cleanroom...

What’s new about the revised Annex 1 guidelines and how...

Continue reading
July 30, 2024 3 Mins Read
Non-Document Identity Verification: The Future?

Digital identity verification still relies on clients needing to locate...

Continue reading
July 30, 2024 4 Mins Read

Request Brochure

Fill out the form and we will contact you as soon as possible

    First Name*

    Last Name*

    Company*

    Corporate Email*

    Phone Number*

    Conference Name*

    Comments